Background Lupus nephritis (LN) is a common manifestation of systemic lupus erythematosus (SLE), with 10–30% progressing to end-stage renal disease (ESRD) and requiring dialysis. Kidney ...

Background Belimumab in conjunction with mycophenolate mofetil has been proven to be effective for treating systemic lupus erythematosus (SLE) in several randomized controlled trials. Usefulness of ...

Background Although the safety profile of COVID-19 vaccines was shown to be acceptable in the clinical trials, risk and benefit of the vaccines in patients with systemic lupus erythematosus (SLE) are ...

Background Despite the advances in the management of systemic lupus erythematosus (SLE), mortality rate among patients with SLE significantly remained higher compared to non-SLE over time. Serious ...

Background This study aimed to investigate the clinical characteristics, outcomes, and risk factors of patients with a rare but fatal manifestation of systemic lupus erythematosus (SLE), diffusive ...

Background Recently, vitamin D has been shown to play an important role in the immune responses, increasing evidence that it can contribute to the pathogenesis of systemic lupus erythematosus (SLE) as ...

Background Previous US study presented a claims-based algorithm, consisted with comorbidities and medication information, to classify systemic lupus erythematosus (SLE) severity as mild, moderate or ...

Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease with varied clinical manifestations and complex pathogenesis. SLE has a significant impact on morbidity, mortality and ...

Guillermo Ruiz-Irastorza, Diana Paredes-Ruiz, Fernando Arizpe et al. Hydroxychloroquine in patients with systemic lupus erythematosus: how much is enough? Lupus Sci Med 2025;12:e001254. doi: ...

Background Systemic lupus erythematosus (SLE) often mimics the symptoms of other diseases, and the interval between symptom onset and diagnosis remains long in these patients. The aim of this study is ...

Background Around 963 A.D., Bishop Eraclius (Liège, Belgium) wrote an affidavit stating, ‘I … was nearly taken to death by the disease called Lupus.’ On the seventh night of praying at Saint Martin’s ...

Background Tyrosine kinase 2 (TYK2) mediates signaling of key cytokines (eg, Type 1 IFNs, IL-23, and IL-12) involved in lupus pathogenesis. Deucravacitinib is a first-in-class, oral, selective, ...